H2 RECEPTOR ANTAGONIST MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

H2 Receptor Antagonist Market, By Drug Type (Famotidine, Ranitidine, Nizatidine, Cimetidine, Others), By Dosage Form (Tablets, Capsules, Liquids, Powders, Others), By Indication (Gastroesophageal Reflux Disease (GERD), Peptic Ulcers, Zollinger-Ellison Syndrome, Others), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

In August 2023, Upsher-Smith Laboratories, LLC, a pharmaceutical company in the U.S., announced the launch of Famotidine for Oral Suspension, USP. The Therapeutic Equivalence (TE) code for Upsher-Smith's product is AB, and the original Reference Listed Drug (RLD) was Pepcid (famotidine) oral suspension.
In June 2022, Zydus Lifesciences, an India pharmaceutical company, announced that it had received final approval from the US Food and Drug Administration to offer famotidine tablets, an antacid, in the U.S. market
In September 2020, Amneal Pharmaceuticals, Inc., a publicly traded generic and specialty pharmaceutical company, announced that their nizatidine oral solution 15 mg/mL (75 mg/5 mL) is now available for reordering. The medicine, a generic version of Axid, is the only oral liquid form of nizatidine available in the U.S. The Amneal product satisfies all FDA criteria and National Disaster Management Authority (NDMA) specifications.
In October 2020, Reddy's Laboratories Ltd., a multinational pharmaceutical company, announced the relaunch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC, in the U.S., following U.S. Food and Drug Administration (FDA) approval.